Medical news today: Thursday, October 29, 2026
Lilly's retatrutide tops Ozempic, India orders batch tests of medicine ingredients, and FDA opens a gene-therapy pathway
Get tomorrow's issue in your inbox.
- 01
US dermatologists issue new care guidelines for hidradenitis suppurativa
Source: Medical Xpress
The American Academy of Dermatology and the Hidradenitis Suppurativa Foundation have published evidence-based guidelines for managing hidradenitis suppurativa (HS), a long-lasting skin condition that causes painful lumps and abscesses in skin folds. The guidelines appeared online on Oct. 20 in the Journal of the American Academy of Dermatology.
Why it mattersHS is often missed or diagnosed late, so shared guidelines can help patients get consistent care sooner and help insurers judge which treatments are standard, which affects what they cover. More on Cosmetics & skincare →
- 02
Trial finds high-volume Achilles injections no better than sham
Source: MedPage Today
High-volume injections given to ease pain and disability from Achilles tendinopathy (long-term pain and damage in the heel tendon) did not show a significant benefit over sham (fake) injections in a randomized trial of 192 patients split into three groups, MedPage Today reports.
Why it mattersAchilles tendon pain is common in runners and active people; a negative trial like this helps patients and clinics avoid paying for procedures that may not work better than placebo. More on Journal papers →
- 03
Report finds Western Isles prescribes weight-loss drugs at triple Scotland's usual rate
Source: BBC Health
Patients in Scotland's Western Isles are prescribed GLP-1 drugs (diabetes medicines also used for weight loss) at almost three times the rate of any other Scottish health board, a report from the Association of the British Pharmaceutical Industry (ABPI) found. It reported 'significant variation' between boards in access to new medicines, including heart attack and stroke drugs. NHS Western Isles said it is seeing 'significant clinical benefit'; the ABPI noted limits in the data.
Why it mattersWhere you live can shape which new medicines you get on a public health service; the Scottish government says it will 'carefully consider' the findings as it reforms health boards. More on Neurology →
- 04
Study links rare brain disease PSP to living near water-polluting sites
Source: MedPage Today
People living near industrial facilities that polluted the water supply were more likely to develop progressive supranuclear palsy (PSP), a rare and severe brain disease that affects movement, balance and eyesight, according to a study of UK Biobank participants reported by MedPage Today.
Why it mattersThe study shows a link, not proof of cause, but it adds to evidence that environmental pollution may play a role in brain diseases, which matters for clean-water policy and the long-term care costs families face.
- 05
US lawmaker asks watchdog to probe TrumpRx drug-savings claims (STAT+, paywall)
Source: STAT
Rep. Frank Pallone, the top Democrat on the House Energy and Commerce Committee, asked the Government Accountability Office (a congressional watchdog) in an Oct. 27 letter to review whether the TrumpRx website has saved Americans money. The White House says it has saved $700 million since its February launch; TrumpRx does not sell drugs but points people to coupons and discounts. Pallone says key details, including drugmaker price deals, have not been disclosed.
Why it mattersAn independent review could show whether the site really lowers what patients pay at the pharmacy, which matters for anyone relying on it for cheaper medicines.
- 06
US health department lets pharmacies compound six unapproved peptides for now (STAT+, paywall)
Source: STAT
The US Department of Health and Human Services released a policy saying it will use 'enforcement discretion' (choose not to act) against licensed pharmacies, federal facilities and physicians that compound six peptides previously backed by an FDA advisory panel in July. Peptides are short protein-like compounds sold as wellness therapies; STAT notes there is little evidence for many of them, and the FDA is still weighing a final decision.
Why it mattersWider access may make these products easier to buy, but they are not FDA-approved medicines, so buyers should know safety and benefit evidence is limited and insurers are unlikely to pay. More on Approvals & regulatory →
- 07
Biogen posts best quarter since 2020 as Apellis buyout lifts revenue
Source: Fierce Pharma
Biogen's third-quarter revenue beat Wall Street estimates in what Fierce Pharma calls its best quarter since 2020, helped by its acquisition of Apellis. CEO Chris Viehbacher called it 'one of these quarters where the numbers almost just speak for themselves.' Figures are company-reported.
Why it mattersBiogen makes multiple sclerosis, Alzheimer's and rare-disease medicines, so its growth from newer drugs shapes investment and jobs in neurology treatments. Not investment advice. More on Neurology →
Market news · Not investment advice
- 08
Lilly's retatrutide beats Ozempic on blood sugar and weight in diabetes trial
Source: BioPharma Dive
Eli Lilly says the highest dose of its experimental drug retatrutide, which acts on three gut hormones (hence 'triple-G'), beat Novo Nordisk's Ozempic on blood sugar and weight loss in a large diabetes study. It also came with higher rates of side effects and more people stopping treatment. Results are company-reported.
Why it mattersIf approved, it could add a stronger option for type 2 diabetes and weight loss and more price competition in costly GLP-1 drugs, though tolerability will matter to patients. More on Approvals & regulatory →
- 09
GLP-1 users may be a growing market for sports supplements, data suggest
Source: NutraIngredients
NutraIngredients reports that consumer data on people taking GLP-1 weight-loss drugs suggest they are drawn to sports and active nutrition products and may be more supplement-focused than the industry assumes.
Why it mattersExpect more supplements marketed to people on weight-loss jabs; these are industry market findings, not evidence that any product helps, so check claims and ask a pharmacist before adding one. More on Obesity & metabolic →
- 10
FDA unveils 'plug and play' pathway for personalised gene therapies
Source: BioPharma Dive
The US FDA issued guidance offering an approval framework for gene therapies that use a shared design but are tailored to different subsets of patients with the same disease, building on its recent moves to speed 'personalised' treatments.
Why it mattersFamilies with very rare genetic diseases often have no treatment because each tiny group is too small for a full trial; a reusable pathway could bring therapies to them faster. More on Approvals & regulatory →
- 11
Mexican study encapsulates rambutan peel antioxidants for possible supplements
Source: NutraIngredients
Researchers at the Autonomous University of Coahuila in Mexico found that polyphenols (plant antioxidant compounds) from rambutan peel, a fruit waste product, could be encapsulated with sodium alginate at 55% efficiency while keeping significant antioxidant activity, NutraIngredients reports.
Why it mattersThis is lab work on making an ingredient from food waste, not a human health study; it shows how supplement makers look for cheaper, 'upcycled' raw materials. More on Nutraceuticals & supplements →
- 12
India's drug regulator orders batch tests of raw materials after cough-syrup deaths
Source: Business Standard
India's Central Drugs Standard Control Organisation (CDSCO) told all state and territory drug regulators, in an Oct. 27 notice, to make manufacturers test every batch of raw materials, including excipients (inactive ingredients) such as propylene glycol, glycerol and sorbitol, and every batch of finished medicine. It follows the deaths of at least 22 children linked to toxic cough syrups in Madhya Pradesh's Chhindwara, and inspections that found some makers were not testing each batch.
Why it mattersContaminated syrup ingredients have killed children in several countries; stricter testing in India, a major global supplier of generic medicines, aims to make everyday medicines safer at home and abroad. More on Approvals & regulatory →
- 13
Bangladesh's Square Pharma reports record profit and 130% cash dividend
Source: The Business Standard
Square Pharmaceuticals, Bangladesh's leading drugmaker, reported a record consolidated net profit of Tk2,770 crore for FY26, up 16% from Tk2,396 crore, and recommended its highest-ever cash dividend of 130% (Tk13 per share). It also approved Tk725 crore to expand production capacity.
Why it mattersMore local production capacity in Bangladesh can support supply of affordable medicines in South Asia and Africa and create pharma jobs. Not investment advice. More on Approvals & regulatory →
Market news · Not investment advice
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
